These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33109737)

  • 1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
    Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
    Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
    J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
    Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
    Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China.
    Chen J; Wang M; Qi X; Long H; Qi N; Wu L; Ke M; Shao S; Li P; Chen Y; Wang W; Zhu S; Qi X; Li G
    Clin Genitourin Cancer; 2024 Jun; 22(3):102093. PubMed ID: 38762350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
    Wang P; Xia L
    BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
    Qu W; Fu C; Han W; Luo H; Quan J; Chen L; Liao Y; Hu C; Hu H; Niu Y; Xu D; Chen M; Chen J; Liu Y; Chen G; Luo Z; Shi B; Sun Y; Zhou F; Zhou A
    Eur J Cancer; 2024 Jul; 205():114096. PubMed ID: 38772302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
    Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
    Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
    Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
    Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
    Sotelo M; Alonso-Gordoa T; Gajate P; Gallardo E; Morales-Barrera R; Pérez-Gracia JL; Puente J; Sánchez P; Castellano D; Durán I
    Clin Transl Oncol; 2021 Apr; 23(4):882-891. PubMed ID: 32897497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
    Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
    EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
    Sheng X; Chen H; Hu B; Yao X; Liu Z; Yao X; Guo H; Hu Y; Ji Z; Luo H; Shi B; Liu J; Wu J; Zhou F; He Z; Fan J; Wang W; Feng H; Yao S; Keegan P; Huang Y; Guo J
    Clin Cancer Res; 2022 Feb; 28(3):489-497. PubMed ID: 34740921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
    Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
    Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
    JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
    Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
    JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
    Loriot Y; Petrylak DP; Rezazadeh Kalebasty A; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Tagawa ST
    Ann Oncol; 2024 Apr; 35(4):392-401. PubMed ID: 38244927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
    Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
    Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.